Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Sesen Bio","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$12.0 million","newsHeadline":"Sesen Bio Signs Exclusive License Agreement with Qilu Pharmaceutical for the Development and Commercialization of Vicineum\u2122 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Quantum Genomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$50.0 million","newsHeadline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Cend Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Peptron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ECI Pharmaceuticals LLC Signs Agreement to Be Exclusive U.S. Distributor of Generic Cialis\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"$40.0 million","newsHeadline":"Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qilu Pharmaceutical Announces the Latest Results from its Clinical Study on QL1706, in Combination with Chemotherapy, as a First-Line Treatment for Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Qilu Pharmaceutical Co Ltd

    Menu

    Qilu Pharmaceutical Co Ltd

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Qilu Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qilu Pharmaceutical Announces the Latest Results from its Clinical Study on QL1706, in Combination with Chemotherapy, as a First-Line Treatment for Recurrent or Metastatic ...

              Details:

              QL1706 (iparomlimab and tuvonralimab) in combination with chemotherapy, with or without bevacizumab, as a first-line treatment of recurrent or metastatic cervical cancer (r/mCC).

              Lead Product(s): Iparomlimab,Tuvonralimab

              Therapeutic Area: Oncology Product Name: QL1706

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qilu Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Maca...

              Details:

              Under the terms of the agreement, Qilu Pharmaceutical will gain the rights for the development and commercialization of AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan.

              Lead Product(s): GalNAc-RNAi,Pegylated Interferon alpha 2a

              Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729

              Highest Development Status: Phase II Product Type: Large molecule

              Recipient: Arbutus Biopharma

              Deal Size: $300.0 million Upfront Cash: $40.0 million

              Deal Type: Partnership December 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qilu Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ECI Pharmaceuticals LLC Signs Agreement to Be Exclusive U.S. Distributor of Generic Cialis®

              Details:

              Cialis®, and the generic equivalent Tadalafil, is in a class of medications called phosphodiesterase (PDE) inhibitors. Tadalafil is used to treat erectile dysfunction and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate).

              Lead Product(s): Tadalafil

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: ECI Pharmaceuticals LLC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qilu Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC

              Details:

              Under the terms of the agreement, Peptron grants Qilu an exclusive global right and license to develop, manufacture, sell, and commercialize PAb001-ADC for the treatment of cancers.

              Lead Product(s): PAb001-ADC

              Therapeutic Area: Oncology Product Name: PAb001-ADC

              Highest Development Status: IND Enabling Product Type: Large molecule

              Recipient: Peptron

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qilu Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®

              Details:

              Cend presented favorable clinical results at the European Society for Molecular Oncology (ESMO) meeting September 2020 and is advancing into Phase 2 clinical trials in pancreatic cancer with CEND-1 in combination with gemcitabine and nab-paclitaxel.

              Lead Product(s): CEND-1,Gemcitabine,Paclitaxel

              Therapeutic Area: Oncology Product Name: CEND-1

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Cend Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qilu Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical

              Details:

              Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.

              Lead Product(s): Firibastat

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Quantum Genomics

              Deal Size: Undisclosed Upfront Cash: $50.0 million

              Deal Type: Licensing Agreement October 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qilu Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sesen Bio Signs Exclusive License Agreement with Qilu Pharmaceutical for the Development and Commercialization of Vicineum™ in Greater China

              Details:

              Companies have entered into an exclusive licensing agreement for the manufacture, development and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and other types of cancer in China, Hong Kong, Macau and Taiwan.

              Lead Product(s): Vicineum

              Therapeutic Area: Oncology Product Name: VB4-845

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Sesen Bio

              Deal Size: $35.0 million Upfront Cash: $12.0 million

              Deal Type: Agreement July 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY